INIS
drugs
100%
genotype
100%
diseases
66%
transformations
66%
inhibition
66%
cysts
66%
growth
33%
screening
33%
biology
33%
pathogens
33%
in vitro
33%
viability
33%
pathogenesis
33%
bioassay
33%
clinical trials
33%
Pharmacology, Toxicology and Pharmaceutical Science
Acanthamoeba castellanii
100%
Proteasome Inhibitor
100%
Proteasome
40%
Trophozoite
40%
Non Communicable Disease
40%
Acanthamoeba Infection
40%
Infectious Agent
20%
Cyst (Resting Stage)
20%
Clinical Trial
20%
Multiple Myeloma
20%
Acanthamoeba
20%
Amebic Infection
20%
Bortezomib
20%
Medicine and Dentistry
Acanthamoeba
100%
Proteasome Inhibitor
100%
Non Communicable Disease
40%
Acanthamoeba Infection
40%
Proteasome
40%
In Vitro
20%
Protein Degradation
20%
Cell Function
20%
Multiple Myeloma
20%
Pathogen
20%
Clinical Trial
20%
Chemotherapy
20%
Amebic Infection
20%
Bortezomib
20%
Immunology and Microbiology
Acanthamoeba castellanii
100%
Proteasome
100%
Acanthamoeba
42%
Infectious Disease
28%
Trophozoite
28%
Infectious Agent
14%
Cell Function
14%
Protein Degradation
14%
Cyst (Resting Stage)
14%
Multiple Myeloma
14%